Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

被引：0
|
作者：
Ntanasis-Stathopoulos, Ioannis [1 ]
Katodrytou, Eirini [2 ]
Hatjiharissi, Evdoxia [3 ]
Spanoudakis, Emmanouil [4 ]
Douka, Vasiliki [5 ,6 ]
Fotiou, Despina [1 ]
Labropoulou, Vasiliki [7 ]
Dalampira, Dimitra [2 ]
Spiliopoulou, Vasiliki [1 ]
Papadopoulou, Theodosia [2 ]
Christoulas, Dimitrios [8 ]
Malandrakis, Panagiotis [1 ]
Bouchla, Anthi [9 ]
Pappa, Vasiliki [10 ]
Kastritis, Efstathios [1 ]
Terpos, Evangelos [1 ]
Dimopoulos, Meletios [1 ]
Gavriatopoulou, Maria [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
[2] Theagenio Canc Hosp, Dept Hematol, Thessaloniki, Greece
[3] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Sch Med, Dept Internal Med 1,Div Hematol, Thessaloniki, Greece
[4] Univ Hosp Alexandroupolis, Dept Hematol, Alexandroupolis, Greece
[5] Papanikolaou Gen Hosp, Dept Hematol, Thessaloniki, Greece
[6] Papanikolaou Gen Hosp, Bone Marrow Transplantat Unit, Thessaloniki, Greece
[7] Univ Patras, Med Sch, Div Hematol, Patras, Greece
[8] 251 Gen AirForce Hosp, Dept Haematol, Athens, Greece
[9] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Internal Med 2, Hematol Div, Haidari, Greece
[10] Attikon Gen Hosp, Dept Hematol, Athens, Greece
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-206900
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6988 / 6990
页数：3
相关论文
共 50 条
  • [41] Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma
    Bruno, Amanda S.
    Willson, Jenny L.
    Opalinska, Joanna M.
    Nelson, Jeanenne J.
    Lunacsek, Orsolya E.
    Stafkey-Mailey, Dana R.
    Willey, Joanne P.
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 1017 - 1025
  • [42] Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma.
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeanenne Joy
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Real-World Outcomes for Standard-ofCare Treatments in Patients with Relapsed/Refractory Multiple Myeloma
    Delforge, Michael
    Vekemans, Marie-Christiane
    Anguille, Sebastien
    Depaus, Julien
    Meuleman, Nathalie
    Van de Velde, Ann
    Van de Broek, Isabelle
    Strens, Danielle
    Van Hoorenbeeck, Sandra
    Moorkens, Evelien J.
    Diels, Jorks
    Ghilotti, Francesca
    Dalhuisen, Sander
    Vandervennet, Sophie
    BLOOD, 2021, 138
  • [44] Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis
    Dong, Sharlene
    Banerjee, Rahul
    Khan, Adeel
    Wang, Mengru
    Wang, Xiaoliang
    Afghahi, Anosheh
    Afrough, Aimaz
    Janakiram, Murali
    Wang, Bo
    Cowan, Andrew
    Sperling, Adam
    Anderson, Larry
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S258 - S259
  • [45] Real-world outcomes of daratumumab monotherapy in relapsed/refractory myeloma
    Maouche, N.
    Leary, H.
    Collings, F.
    Tseu, B.
    Djebbari, F.
    Vallance, G.
    Ramasamy, K.
    Kothari, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 125 - 125
  • [46] The real-world outcomes of multiple myeloma patients treated with daratumumab
    Szabo, Agoston Gyula
    Klausen, Tobias Wirenfeldt
    Levring, Mette Boegh
    Preiss, Birgitte
    Helleberg, Carsten
    Breinholt, Marie Fredslund
    Hermansen, Emil
    Gjerdrum, Lise Mette Rahbek
    Bonlokke, Soren Thorgaard
    Nielsen, Katrine
    Kjeldsen, Eigil
    Iversen, Katrine Fladeland
    Teodorescu, Elena Manuela
    Dokhi, Marveh
    Kurt, Eva
    Strandholdt, Casper
    Andersen, Mette Klarskov
    Vangsted, Annette Juul
    PLOS ONE, 2021, 16 (10):
  • [47] Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab
    Richter, Joshua
    Anupindi, Vamshi Ruthwik
    Yeaw, Jason
    Kudaravalli, Suneel
    Zavisic, Stojan
    Shah, Drishti
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 395 - 409
  • [48] Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
    Mian, Hira
    Tan, Carlyn Rose
    Asoori, Sireesha
    Popat, Rakesh
    Abdallah, Nadine
    Chhabra, Saurabh
    Parrondo, Ricardo D.
    Pond, Gregory R.
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    BLOOD, 2024, 144 : 704 - 705
  • [49] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [50] Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma
    Harvey, R. Donald
    Cong, Ze
    Werther, Winifred
    Lethen, Jan L.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
12345